Insider Buying: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Acquires 40,000 Shares of Stock

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Jonathan C. Javitt acquired 40,000 shares of the stock in a transaction dated Tuesday, December 17th. The stock was acquired at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the purchase, the chairman now directly owns 84,634 shares in the company, valued at approximately $99,021.78. The trade was a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

NRx Pharmaceuticals Trading Down 5.8 %

Shares of NASDAQ:NRXP opened at $1.55 on Thursday. NRx Pharmaceuticals, Inc. has a 1 year low of $1.10 and a 1 year high of $7.33. The stock has a market capitalization of $18.69 million, a PE ratio of -0.72 and a beta of 1.25. The firm has a fifty day moving average price of $1.28 and a 200 day moving average price of $1.88.

Institutional Investors Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP purchased a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned about 1.33% of NRx Pharmaceuticals as of its most recent SEC filing. 4.27% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on NRXP shares. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st. Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Finally, HC Wainwright restated a “buy” rating and set a $19.00 price target on shares of NRx Pharmaceuticals in a report on Monday, November 25th.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.